Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry

Cecilie Hveding Blimark,1 Ingemar Turesson,2 Anna Genell,3 Lucia Ahlberg,4 Bo Björkstrand,5 Kristina Carlson,6 Karin Forsberg,7 Gunnar Julliussen,8 Olle Linder,9 Ulf-Henrik Mellqvist,1,10 Hareth Nah11 and Sigurdur Y. Kristinsson12,13

1Department of Hematology, Sahlgrenska University Hospital and Institution of Internal Medicine, Sahlgrenska Academy at University of Gothenburg, Sweden; 2Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund-Malmö, Sweden; 3Regional Cancer Center West, Western Sweden Health Care Region, Gothenburg, Sweden; 4Division of Hematology, Linkoping University Hospital, Linkoping, Sweden; 5Internal Medicine /Hematology, Karolinska Institutet, Stockholm, Sweden; 6Department of Hematology, Uppsala University Hospital, Sweden; 7Department of Hematology, Umeå University Hospital, Sweden; 8Hematology/Transplantation, Stem Cell Center, Lund University, Sweden; 9Department of Hematology, Orebro University Hospital, Sweden; 10Department of Hematology, Borås Hospital, Sweden; 11Division of Hematology, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden; 12Department of Medicine and Division of Hematology, University of Iceland, Reykjavik, Iceland and 13Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden; for the Swedish Myeloma Registry

©2018 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2017.178103

Received: August 4, 2017.
Accepted: December 7, 2017.
Pre-published: December 7, 2017.
Correspondence: cecilie.blimark@vgregion.se
### SUPPLEMENTAL TABLES

#### Table S1: Observed and relative 1-year, 3-year and 5-year survival (percentages) with 95% confidence interval, by age category, in the Swedish Myeloma Registry (MM+ SMM)

| Age Category | Time int. (Years) | n at risk | Obs. surv. (%) | CI          | Rel. surv. (%) | CI          |
|--------------|-------------------|-----------|----------------|-------------|----------------|-------------|
| 00-49        | 1                 | 208       | 96.8           | 94.5 - 99.2 | 96.9           | 94.6 - 99.3 |
| 50-59        | 1                 | 505       | 93.7           | 91.7 - 95.8 | 94.1           | 92.1 - 96.2 |
| 60-69        | 1                 | 1215      | 88.5           | 86.8 - 90.2 | 89.5           | 87.8 - 91.2 |
| 70-79        | 1                 | 1276      | 82.8           | 81.0 - 84.7 | 85.3           | 83.4 - 87.3 |
| 80-89        | 1                 | 691       | 64.9           | 62.1 - 67.8 | 71.0           | 67.9 - 74.2 |
| 90-           | 1                 | 53        | 45.7           | 37.4 - 55.7 | 59.1           | 48.5 - 72.0 |
| 00-49        | 3                 | 147       | 85.7           | 81.0 - 90.9 | 86.2           | 81.4 - 91.3 |
| 50-59        | 3                 | 332       | 80.9           | 77.5 - 84.5 | 82.0           | 78.6 - 85.6 |
| 60-69        | 3                 | 722       | 71.0           | 68.5 - 73.6 | 73.7           | 71.1 - 76.3 |
| 70-79        | 3                 | 622       | 57.4           | 54.8 - 60.6 | 63.4           | 60.5 - 66.4 |
| 80-89        | 3                 | 267       | 32.8           | 30.0 - 36.0 | 44.0           | 40.2 - 48.2 |
| 90-           | 3                 | 9         | 10.3           | 5.7 - 18.6  | 23.4           | 13.2 - 41.6 |
| 00-49        | 5                 | 86        | 73.1           | 66.5 - 80.3 | 73.8           | 67.2 - 81.1 |
| 50-59        | 5                 | 195       | 68.2           | 63.8 - 72.9 | 70.0           | 65.5 - 74.8 |
| 60-69        | 5                 | 357       | 56.1           | 53.1 - 59.3 | 60.0           | 56.8 - 63.4 |
| 70-79        | 5                 | 268       | 37.3           | 34.4 - 40.3 | 45.0           | 41.6 - 48.7 |
| 80-89        | 5                 | 64        | 13.4           | 11.0 - 16.2 | 23.2           | 19.2 - 28.1 |
| 90-           | 5                 | 0         | 4.6            | 1.8 - 11.7  | 12.3           | 5.8 - 26.2  |

#### Table S2: Observed and relative 1-year, 3-year and 5-year survival (percentages) with 95% confidence interval, by diagnosis

| Diagnosis | Time int. (Years) | n at risk | Obs. surv. (%) | CI          | Rel. surv. (%) | CI          |
|-----------|-------------------|-----------|----------------|-------------|----------------|-------------|
| MM        | 1                 | 3112      | 79.0           | 77.8 - 80.3 | 81.8           | 80.5 - 83.1 |
| SMM       | 1                 | 836       | 92.0           | 90.3 - 93.8 | 95.4           | 93.6 - 97.3 |
| MM        | 3                 | 1611      | 55.0           | 53.4 - 56.7 | 60.7           | 59.0 - 62.6 |
| SMM       | 3                 | 488       | 74.5           | 71.5 - 77.6 | 83.4           | 80.1 - 86.9 |
| MM        | 5                 | 726       | 38.3           | 36.5 - 40.1 | 44.9           | 42.9 - 47.1 |
| SMM       | 5                 | 246       | 57.2           | 53.4 - 61.1 | 69.4           | 64.9 - 74.2 |

#### Table S3: Observed and relative median survival, by diagnosis all patient reportad at diagnosis

| Diagnosis | Observed median survival (Years) | Relative median survival (Years) |
|-----------|---------------------------------|---------------------------------|
| MM        | 3.50                            | 4.23                            |
| SMM       | 5.96                            | 8.01                            |
### Table S4: Observed and relative median survival in MM, by 10 year cohorts

| 10 Year Cohort | Observed Median Survival (Years) | Relative Median Survival (Years) |
|----------------|----------------------------------|---------------------------------|
| 00-49          |                                  |                                 |
| 50-59          | 7.78                             | 8.11                            |
| 60-69          | 5.37                             | 5.92                            |
| 70-79          | 3.34                             | 3.90                            |
| 80-89          | 1.53                             | 2.01                            |
| 90-             | 0.75                             | 1.31                            |

### Table S5: Survival by response grade in MM patients, all ages

| Response | Time int. (Years) | n at risk | Obs. surv. (%) | CI          | Rel. surv. (%) | CI          |
|----------|-------------------|-----------|----------------|-------------|----------------|-------------|
| CR       | 1                 | 339       | 97.7           | 96.1 - 99.3 | 99.2           | 97.6 - 100.8|
| VGPR     | 1                 | 1012      | 94.8           | 93.4 - 96.1 | 96.7           | 95.4 - 98.1 |
| PR       | 1                 | 973       | 88.9           | 87.1 - 90.8 | 91.8           | 89.8 - 93.8 |
| No response | 1     | 379       | 64.8           | 61.1 - 68.8 | 67.2           | 63.2 - 71.4 |
| CR       | 3                 | 239       | 81.7           | 77.7 - 86.0 | 85.3           | 80.9 - 89.8 |
| VGPR     | 3                 | 660       | 72.1           | 69.4 - 74.9 | 76.9           | 74.0 - 79.9 |
| PR       | 3                 | 568       | 58.6           | 55.7 - 61.7 | 64.9           | 61.6 - 68.4 |
| No response | 3     | 185       | 35.5           | 31.8 - 39.7 | 40.2           | 35.9 - 45.1 |
| CR       | 5                 | 112       | 64.1           | 58.6 - 70.2 | 69.1           | 63.0 - 75.8 |
| VGPR     | 5                 | 315       | 54.1           | 50.8 - 57.5 | 60.2           | 56.5 - 64.1 |
| PR       | 5                 | 264       | 38.9           | 35.9 - 42.2 | 45.9           | 42.2 - 49.9 |
| No response | 5     | 76        | 19.7           | 16.5 - 23.5 | 24.7           | 20.6 - 29.8 |

### Table S6: Observed and relative 1-year, 3-year and 5-year survival (percentages) with 95% confidence interval, in MM, by period of diagnosis (Period 1 2008-2010, Period 2 2011-2015)

| Diag. period | Time int. (Years) | n at risk | Obs. surv. (%) | CI          | Rel. surv. (%) | CI          |
|--------------|-------------------|-----------|----------------|-------------|----------------|-------------|
| 1            | 1                 | 1468      | 80.4           | 78.6 - 82.3 | 83.2           | 81.3 - 85.1 |
| 2            | 1                 | 2480      | 82.1           | 80.8 - 83.5 | 85.1           | 83.7 - 86.5 |
| 1            | 3                 | 1034      | 56.7           | 54.5 - 59.1 | 62.6           | 60.1 - 65.2 |
| 2            | 3                 | 1065      | 60.0           | 58.1 - 61.9 | 66.6           | 64.5 - 68.8 |
| 1            | 5                 | 732       | 40.1           | 38.0 - 42.5 | 47.3           | 44.7 - 50.0 |
| 2            | 5                 | 240       | 43.3           | 40.9 - 45.9 | 51.3           | 48.4 - 54.3 |
Table S7: Observed and relative 1-year, 3-year and 5-year survival (percentages) with 95 % confidence interval, by hospital type (uni./not uni. hosp.)

| Hospital type          | Time Int. (Years) | n at risk | Obs. surv. (%) | CI      | Rel. surv. (%) | CI      |
|-----------------------|-------------------|-----------|----------------|---------|----------------|---------|
| Not university hospital | 1                 | 1622      | 77.7           | 75.9 - 79.5 | 80.0          | 78.1 - 81.9 |
| University hospital   | 1                 | 1216      | 82.9           | 81.0 - 84.8 | 85.0          | 83.0 - 87.0 |
| Not university hospital | 3                 | 964       | 52.5           | 50.4 - 54.7 | 57.3          | 54.9 - 59.8 |
| University hospital   | 3                 | 762       | 60.4           | 58.0 - 63.0 | 65.6          | 62.9 - 68.5 |
| Not university hospital | 5                 | 424       | 35.2           | 33.1 - 37.6 | 41.5          | 38.9 - 44.3 |
| University hospital   | 5                 | 375       | 44.3           | 41.6 - 47.2 | 49.9          | 46.7 - 53.3 |
Figure S1: Age specific incidens (per 100 000 personyears) of myeloma (including plasmocytoma) in Sweden, Data from The Swedish National Health Board, mean over the years 2008–2015

Figure S2: Observed and relative survival in myeloma (SMM+MM) patients by age cohorts In the Swedish Myeloma Registry
Figure S3: Relative survival by period of diagnosis, by age cohort (≤65, 66–79, ≥80)